Helio Pedro, MD
Internal Medicine · Newark, NJNPI 1215983382
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,735 of the $116,208 with a category attached, or 66.9%. Sanofi accounts for 84.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $36,339 and has fallen 99.9% since, to $35 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $1529.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$98K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Ultragenyx Pharmaceutical Inc.$3K
- Amgen$2K
- Amicus Therapeutics, Inc.$2K
- AstraZeneca$1K
- plus $220 from 5 others
Across 150 payments — averaging $11,087 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$945K
- Amicus Therapeutics, Inc.$494K
- Shire North American Group Inc$138K
- AstraZeneca$46K
- Sanofi$18K
- Sanofi US Services Inc.$17K
- plus $5K from 2 others
What the payments were for
- Consulting fees$35,62231%
- Speaking & faculty fees$77,73567%
- Travel & lodging$1,6181%
- Food & beverage$1,1551%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 56 | $97,567 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $9,586 |
| Ultragenyx Pharmaceutical Inc. | 2 | $3,230 |
| Amgen | 3 | $2,379 |
| Amicus Therapeutics, Inc. | 1 | $2,200 |
| AstraZeneca | 2 | $1,026 |
| Biomarin Pharmaceutical Inc. | 2 | $115 |
| Sanofi-aventis U.S. LLC | 1 | $56 |
| PTC Therapeutics, Inc. | 1 | $35 |
| Shire North American Group Inc | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,208 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VimizimElosulfase Alfa | 12 | $507,684 |
| VprivVelaglucerase Alfa | 11 | $447,380 |
| ZavescaMiglustat | 13 | $220,121 |
| Betaine AnhydrousBetaine | 23 | $67,930 |
| Leucovorin Calcium | 12 | $1,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biomarin Pharmaceutical Inc.Vimizim | $115 | $507,68412 claims |
| Shire North American Group IncVpriv | $12 | $447,38011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Newark
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.